Status:
COMPLETED
Sarcosine (N-Methylglycine) Monotherapy for Schizophrenia
Lead Sponsor:
China Medical University Hospital
Collaborating Sponsors:
National Health Research Institutes, Taiwan
National Science and Technology Council, Taiwan
Conditions:
Schizophrenias
Psychoses
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
Brief Summary
The etiology of schizophrenia remains unclear. Schizophrenia patients reveal positive symptoms, negative symptoms, and cognitive impairments. In addition to dopamine system hyperactivity, hypofunction...
Detailed Description
In the study, 20 schizophrenic patients are recruited into the 6-week trial and randomly assigned into the two groups (1 g/d and 2 g/d) with a double-blind manner. Clinical manifestation (Positive and...
Eligibility Criteria
Inclusion
- Fulfill the criteria of schizophrenia according to the Diagnostic and Statistic Manual, fourth edition (DSM-IV).
- Free from antipsychotics for at least 7 days before enrollment.
- Agree to participate in the study and provide informed consent
Exclusion
- Meet DSM-IV criteria of major mood disorder, current substance dependence or mental retardation
- History of epilepsy, head trauma or CNS diseases
- Major, untreated medical diseases
- Pregnancy or lactation
- Receiving psychotropic agents or depot within three months prior to study entry
Key Trial Info
Start Date :
December 1 2004
Trial Type :
INTERVENTIONAL
End Date :
December 1 2005
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00328276
Start Date
December 1 2004
End Date
December 1 2005
Last Update
May 19 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Psychiatry, China Medical University Hospital
Taichung, Taiwan, 404